Can you describe the gene editing process involved in creating cema-cel to mitigate the risk of graft-vs-host disease? Cemacabtagene ansegedleucel, or cema-cel, is an allogeneic CAR T-cell therapy ...
Shortly after this publication, Bogdanove struck up a collaboration with Daniel Voytas, a plant geneticist at the University ...
In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...
The Times of Israel on MSN2d
Israeli researchers use gene editing to eliminate 50% of head, neck tumors in miceTel Aviv University scientists say that they can inject CRISPR genetic 'molecular scissors' to shrink tumors by 90%; ...
Researchers are using gene editing techniques to introduce beneficial traits like polled and disease resistance, as well as ...
The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.
Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback